Skip to content

Lupin Limited

LUPIN · 500257 · Healthcare · Pharmaceuticals

Full report
Rs 1,989.9+17.2 (+0.87%)
Market cap
Rs 90,988 Cr
P/E
16.44x
P/B
4.05x
52W high / low
Rs 2,529.5 / Rs 1,892.9

Our computed operating_margin (26.45%) diverges from BSE's own published figure (53.84%) by more than 100%. BSE's figure is a different, BSE-computed number (not necessarily TTM, standalone-only) — treat as a cross-check/fallback signal, not proof either figure is wrong. Our computed net_margin (18.52%) diverges from BSE's own published figure (41.33%) by more than 100%. BSE's figure is a different, BSE-computed number (not necessarily TTM, standalone-only) — treat as a cross-check/fallback signal, not proof either figure is wrong.

About Lupin

Lupin Limited is listed on the NSE under the symbol LUPIN and on the BSE under scrip code 500257. It is classified in the Healthcare sector, industry: Pharmaceuticals. It is a constituent of BSE 100, NIFTY 200, NIFTY 500, NIFTY Midcap 150 and NIFTY Pharma. The company listed on 10 Sept 2001 and has a face value of Rs 2.

The latest available end-of-day price is Rs 1,989.9 (+0.87% on the day), for a market capitalisation of Rs 90,988 Cr. Trailing P/E is 16.44x and price-to-book is 4.05x. The 52-week range is Rs 1,892.9 to Rs 2,529.5. The latest price is 15% of the way from the 52-week low to the 52-week high.

Against the 15-company comparison set from the official BSE basic industry Pharmaceuticals, its market capitalisation is 0.8 times the peer median of Rs 1,09,706 Cr, and its P/E of 16.44x compares with a peer median of 36.40x. The comparison set is chosen mechanically from the exchange classification; it is not a ranking.

Latest annual results

For FY26 (year ended 31 Mar 2026), Lupin Limited reported revenue of Rs 27,958 Cr and net profit of Rs 5,355 Cr, with a net margin of 19.16% and earnings per share of Rs 116.75 (consolidated statements).

Year-on-year change: revenue +23.92%; net profit +61.98%; EPS +62.27%. Three-year compound annual growth rate: revenue +19.30%; net profit +128.66%.

At the same date the balance sheet shows total assets of Rs 38,365 Cr, shareholders' equity of Rs 22,448 Cr, total debt of Rs 5,910 Cr, cash of Rs 4,168 Cr, a debt-to-equity ratio of 0.26 and operating cash flow of Rs 7,546 Cr.

On a trailing-twelve-month basis the filings add up to revenue of Rs 29,967 Cr, net income of Rs 5,551 Cr and a net margin of 18.52%.

Shareholding pattern

In the shareholding pattern for 30 Sept 2026, Lupin Limited's ownership is split: promoters 46.84%; foreign institutional investors (FIIs) 23.28%; domestic institutional investors (DIIs) 23.78%; retail and other shareholders 6.10%.

Compared with the filing for 30 Jun 2026: promoter holding −0.01 percentage points; FII holding +0.86 percentage points; DII holding −0.87 percentage points.

The same filing lists reported promoter pledge of 0.00% and 2,97,301 shareholders on record.

Recent filings and corporate actions

177 BSE corporate announcements were filed by Lupin Limited in the past twelve months; the most frequent category is "Company Update" (154). The most recent is "U.S. FDA has concluded an inspection at Company''s manufacturing facility located in Goa, India." (Company Update), filed on 24 Oct 2026.

The disclosed corporate-action timeline lists 5 entries: dividend (5). The latest is a dividend (Final Dividend - Rs. - 18.0000) with ex-date 17 Jul 2026.

Figures are raw disclosures from official NSE/BSE and SEBI filings plus mechanically computed ratios, restated in words. This is research data, not investment advice, a rating or a recommendation; DalalOS is not a SEBI-registered investment advisor.

More

Peer comparison

Official BSE basic industry: Pharmaceuticals. Limited to companies within a 0.1x–10x market-cap band.

Edit columns
Official-industry peer comparison for Lupin Limited
Sun Pharmaceutical Industries LimitedRs 1,761Rs 4,22,517 CrRs 62,141 CrRs 12,117 Cr34.94x15.53%
Divi's Laboratories LimitedRs 9,664Rs 2,56,096 CrRs 11,682 CrRs 2,925 Cr87.69x18.44%
Torrent Pharmaceuticals LimitedRs 4,580Rs 1,55,015 CrRs 15,654 CrRs 2,156 Cr73.16x27.30%
Laurus Labs LimitedRs 2,244Rs 1,21,232 CrRs 7,323 CrRs 1,091 Cr—22.38%
Zydus Lifesciences LimitedRs 1,184.4Rs 1,18,203 CrRs 29,052 CrRs 4,593 Cr26.40x17.68%
Dr. Reddy's Laboratories LimitedRs 1,345Rs 1,12,308 CrRs 34,353 CrRs 2,760 Cr40.02x7.84%
Cipla LimitedRs 1,358Rs 1,09,706 CrRs 28,855 CrRs 2,854 Cr37.86x8.83%
Mankind Pharma LimitedRs 2,469.3Rs 1,01,982 CrRs 15,705 CrRs 2,264 Cr45.45x14.78%
Aurobindo Pharma LimitedRs 1,659.9Rs 95,511 CrRs 35,625 CrRs 3,711 Cr25.94x10.53%
Lupin LimitedThis companyRs 1,989.9Rs 90,988 CrRs 30,442 CrRs 5,551 Cr16.44x27.89%
Glenmark Pharmaceuticals LimitedRs 2,339Rs 66,007 CrRs 18,236 CrRs 1,798 Cr36.71x15.46%
Alkem Laboratories LimitedRs 5,079Rs 60,719 CrRs 15,681 CrRs 2,204 Cr28.15x16.72%
Biocon LimitedRs 351.9Rs 57,346 CrRs 17,638 CrRs 416 Cr—1.78%
Abbott India LimitedRs 26,145Rs 55,558 CrRs 7,295 CrRs 1,615 Cr34.41x35.85%
Gland Pharma LimitedRs 3,074.5Rs 50,717 CrRs 7,045 CrRs 1,129 Cr44.88x11.57%
MedianRs 2,244Rs 1,09,706 CrRs 15,705 CrRs 2,760 Cr36.40x16.72%

Peers are selected mechanically from the official BSE industry hierarchy and current market-cap band. This is a comparison set, not a ranking or recommendation.

Loading stock details

Companies related to Lupin

Same official industry (Pharmaceuticals)

Other Healthcare companies of a similar market capitalisation

Companies are grouped mechanically from the exchange classification and listed by market capitalisation. This is a comparison set, not a ranking or recommendation.

Explore further